Introduction {#sec1}
============

Breast cancer is now the most common malignancy among women worldwide \[[@B1],[@B2]\]. Although precise surgery and adjuvant systemic treatments including chemotherapeutic agents, radiotherapy, hormone therapy, and molecular targeting drugs greatly improve the overall outcome, the prognosis of breast cancer remains poor. The limitation of clinical, pathological, and molecular features in individualized tumor therapy urgently requires a novel approach to predict outcome and treatment response. Therefore, finding some more available and effective markers as surrogates of these features is of crucial importance \[[@B3]\].

As a mitotic spindle checkpoint gene, baculoviral inhibitor of apoptosis repeat containing 5 (*BIRC5*, also known as survivin) has been shown to play vital roles in carcinogenesis by influencing cell division and proliferation and by inhibiting apoptosis \[[@B4]\]. Since *BIRC5* is frequently overexpressed in a majority of malignancies \[[@B5]\], treatment that targets *BIRC5* has been increasingly noticed as a novel strategy for various malignant tumors. For example, inactivation of nuclear export signal for *BIRC5* may increase therapy response in head and neck cancer patients \[[@B8]\]. Both molecular suppression by gene editing approach and pharmacological inhibition by *BIRC5* antagonist could reduce the growth, migration, and invasiveness of ovarian cancer cells \[[@B7]\]. In terms of breast cancer, *BIRC5* was highly expressed in triple-negative subtype and *BIRC5* repression was able to decrease the proliferation of breast cancer cells, implying that *BIRC5* acts like a tumor driver \[[@B9]\]. Moreover, it was demonstrated that *BIRC5* was a pejorative marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy \[[@B10]\]. Besides, *BIRC5* expression has been found to confer resistance to chemotherapy and radiation. Targeting *BIRC5* in experimental models improves survival \[[@B11]\]. Together, these findings indicate that *BIRC5* may not only function as an oncogene, but also as a promising predictive biomarker and potential therapeutic target in cancer \[[@B12]\].

Therefore, the present work was carried out to validate the expression pattern, potential function, prognostic value, and drug interaction network of *BIRC5* in breast cancer by performing bioinformatics analysis of several large online databases.

Materials and methods {#sec2}
=====================

Breast tissue samples {#sec2-1}
---------------------

A total of 18 pairs of breast tissue samples were obtained from the Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University between 2014 and 2016. The collection and use of samples was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of Changzhou No.2 People's Hospital \[[@B13]\]. Informed written consent was received from all patients.

Oncomine {#sec2-2}
--------

The Oncomine (<http://www.oncomine.org>), a database containing publicly available microarray data on multiple tumors, was searched to check the level of *BIRC5* in breast cancer and normal tissues with the options as follows: fold change ≥2, *P*-value ≤1E-4, and the top 10% gene ranking \[[@B14]\]. *BIRC5* co-expression profile was shown in the heatmap.

Ualcan {#sec2-3}
------

The Ualcan (<http://ualcan.path.uab.edu/>), a popular web source for in-depth analysis of The Cancer Genome Atlas (TCGA) data, was used to validate the relative level of *BIRC5* across tumor and normal samples, as well as in tumor subgroups according to different stages \[[@B15]\]. Besides, the promoter methylation level of *BIRC5* in breast cancer and normal tissues was obtained by using Ualcan.

bc-GenExMiner {#sec2-4}
-------------

The Breast Cancer Gene-Expression Miner v4.1 (bc-GenExMiner v4.1, <http://bcgenex.centregauducheau.fr/BC-GEM>), an open access database of published annotated genomics data, was utilized to analyze the relevance between *BIRC5* and specific clinicopathological features of breast cancer \[[@B16],[@B17]\]. Association between *BIRC5* and metastatic relapse event was assessed using the prognostic module, and correlation of *BIRC5* and co-expressed *cell-division cycle protein 20* (*CDC20*) was evaluated using the correlation module.

UCSC Xena {#sec2-5}
---------

The UCSC Xena browser (<http://xena.ucsc.edu/>) was used to analyze the TCGA Breast Cancer data using the level 3 data. The heatmap and correlation between *BIRC5* and *CDC20* were then constructed.

Kaplan--Meier Plotter {#sec2-6}
---------------------

The Kaplan--Meier Plotter (<http://kmplot.com/analysis/>), a web tool capable to check the effect of 54675 genes on survival using 5143 clinical breast cancer samples, was applied to show the prognostic value of *BIRC5* in relapse-free survival, overall survival, and distant metastasis-free survival \[[@B18]\]. The hazard ratio (HR) with 95% confidence interval (CI), and log-rank *P*-value were calculated automatically.

Comparative Toxicogenomics Database {#sec2-7}
-----------------------------------

The Comparative Toxicogenomics Database (<http://ctdbase.org/>) was employed to construct *BIRC5*--drug interaction network \[[@B19]\]. Concretely, *BIRC5* was checked in the database for potential chemical drugs that could decrease/increase the mRNA or protein expression of *BIRC5*. Drugs were picked based on their clinical applications in breast cancer treatment. *BIRC5*--drug interaction network was then generated using the Cytoscape (<http://cytoscape.org/>) \[[@B20],[@B21]\]. *BIRC5* gene was also queried in the database and the results were filtered by selecting *BIRC5*-related pathways.

RNA isolation and real-time PCR and Western blot {#sec2-8}
------------------------------------------------

Total RNA was extracted using the TRIzol reagent (TaKaRa, Japan), and 1000 ng RNA was reverse transcribed into cDNA using the SYBR PrimeScript RT-PCR kit (Takara Bio Inc., Japan) on an iCycler iQ system (Bio-Rad, U.S.A.). Real-time PCR was performed using the same kit on a Light Cycler 480 (Roche, Australia). The primer sequence of *BIRC5* and endogenous control *β-actin* was as follows: forward, 5′‐ATTCGTCCGGTTGCGCTTTCC‐3′; reverse, 5′‐CACGGCGCACTTTCTTCGCAG‐3′; and forward, 5′-GCTGTGCT ATCCCTGTACGC-3′; reverse, 5′-TGCCTCAGGGCAGCGGAACC-3′, respectively. All reactions, including the negative controls, were performed in triplicate.

Tissue proteins were extracted, electrophoresed through SDS/PAGE gel, and transferred to PVDF membranes for Western blot. *BIRC5* protein level was quantified using antibody against *BIRC5* (1:1000, Santa Cruz, U.S.A.). β-actin (Sigma, Germany) was used for normalization. Bound proteins were visualized by using the ECL Plus Kit (Millipore, U.S.A.) with Image Lab Software (Bio-Rad, U.S.A.).

Statistical analysis {#sec2-9}
--------------------

According to protocols of the above tools, mRNA levels of *BIRC5* in breast cancer and normal tissues in each individual dataset were analyzed using the Student's *t* test. Kaplan--Meier survival analysis was performed to compare patient survival based on *BIRC5* expression by log-rank test. Global significant difference between groups of clinical parameters was assessed by Welch's test, along with Dunnett--Tukey--Kramer's.

Results {#sec3}
=======

*BIRC5* expression and methylation status in breast cancer patients {#sec3-1}
-------------------------------------------------------------------

We first measured the *BIRC5* levels in 20 cancer types. Oncomine database revealed that *BIRC5* was significantly higher expressed in breast cancer patients compared with the matched normal individuals ([Figure 1](#F1){ref-type="fig"}A). TCGA data analyzed by the Ualcan online tool confirmed that higher *BIRC5* was expressed in breast cancer tissues than in normal tissues ([Figure 1](#F1){ref-type="fig"}B, *P*\<0.05). Moreover, patients with a more advanced stage of breast cancer tended to express higher levels of *BIRC5* ([Figure 1](#F1){ref-type="fig"}C.) Consistent with the results from databases, we also compared the *BIRC5* expression in breast cancer tissues and adjacent normal tissues in our hospital and found that *BIRC5* was elevated in breast cancer tissues both in mRNA level ([Figure 1](#F1){ref-type="fig"}D) and protein level ([Figure 1](#F1){ref-type="fig"}E). Specifically, increased level of *BIRC5* was observed in medullary breast carcinoma, invasive ductal breast carcinoma, invasive breast carcinoma, invasive ductal and invasive lobular breast carcinoma, breast carcinoma, invasive lobular breast carcinoma, and intraductal cribriform breast adenocarcinoma with respect to normal tissues ([Figure 2](#F2){ref-type="fig"}A--I). Heatmap and DNA methylation status indicated that *BIRC5* expression might be negatively associated with DNA methylation in breast cancer ([Figure 3](#F3){ref-type="fig"}A). Besides, higher promoter methylation level of *BIRC5* was observed in breast cancer tissues, with respect to normal tissues ([Figure 3](#F3){ref-type="fig"}B).

![*BIRC5* expression in breast cancer patients\
(**A**) Expression of *BIRC5* in 20 types of cancer and the matched normal individuals using the Oncomine database. Red and blue indicate the numbers of datasets with statistically significant (*P*\<0.05) higher expressed and lower expressed *BIRC5* gene. (**B**) Higher mRNA *BIRC5* was expressed in breast cancer tissues than in normal tissues (*P*\<0.05) using Ualcan online tool. (**C**) Patients with a more advanced stage of breast cancer tended to express higher levels of *BIRC5* using Ualcan online tool. (**D**) Expression of *BIRC5* in 18 pairs of breast cancer tissues and adjacent normal breast tissues obtained from our own hospital. (**E**) *BIRC5* protein expression in two pairs of breast cancer tissues and adjacent normal breast tissues (*\*, P*\<0.05).](bsr-40-bsr20193678-g1){#F1}

![Box plot comparing *BIRC5* expression in normal tissues and breast cancer patients obtained from the Oncomine database\
Analysis is shown for (**A**) medullary breast carcinoma, (**B**) invasive ductal breast carcinoma, (**C**) invasive breast carcinoma, (**D**) invasive ductal and invasive lobular breast carcinoma, (**E**) breast carcinoma, (**F**) invasive breast carcinoma, (**G**) invasive ductal breast carcinoma, (**H**) invasive lobular breast carcinoma, and (**I**) intraductal cribriform breast adenocarcinoma (*\*, P*\<0.05).](bsr-40-bsr20193678-g2){#F2}

![*BIRC5* methylation status in breast cancer patients\
(**A**) Heatmap of *BIRC5* expression and DNA methylation status using the TCGA data analyzed by the UCSC Xena browser. (**B**) Higher promoter methylation level of *BIRC5* was observed in breast cancer tissues, with respect to normal tissues.](bsr-40-bsr20193678-g3){#F3}

*BIRC5* expression and clinicopathological features in breast cancer patients {#sec3-2}
-----------------------------------------------------------------------------

We checked the relevance of *BIRC5* expression and different clinicopathological features by using the bc-GenExMiner web-based tool. No significant difference could be found between ≤51- and \>51-year groups ([Figure 4](#F4){ref-type="fig"}A and [Table 1](#T1){ref-type="table"}). Breast cancer patients with more advanced Scarff--Bloom--Richardson (SBR) grade and Nottingham Prognostic Index (NPI) showed elevated *BIRC5* gene \[[@B22],[@B23]\] ([Figure 4](#F4){ref-type="fig"}B,C). Hormone receptor status was found to correlate negatively with *BIRC5* ([Figure 4](#F4){ref-type="fig"}D,E and [Table 1](#T1){ref-type="table"}); whereas human epidermal growth factor receptor-2 (HER-2) status was positively associated with *BIRC5* level ([Figure 4](#F4){ref-type="fig"}F and [Table 1](#T1){ref-type="table"}). In terms of nodal status, no significant difference was found between positive group and negative group ([Figure 4](#F4){ref-type="fig"}G and [Table 1](#T1){ref-type="table"}). Our results also demonstrated strongly higher *BIRC5* expression in basal-like and triple-negative breast cancer patients with respect to non-basal-like and non-triple-negative patients ([Figure 4](#F4){ref-type="fig"}H,I and [Table 1](#T1){ref-type="table"}).

![Box plot evaluating the relevance of *BIRC5* expression and different clinicopathological features using the bc-GenExMiner web-based tool\
Analysis is shown for (**A**) age, (**B**) SBR, (**C**) NPI, (**D**) ER, (**E**) PR, (**F**) HER-2, (**G**) nodal status, (**H**) basal-like status, and (**I**) triple-negative status. Abbreviations: ER, estrogen receptor; PR, progesterone receptor (*\*, P*\<0.05).](bsr-40-bsr20193678-g4){#F4}

###### Relevance of *BIRC5* expression and different clinicopathological features using the bc-GenExMiner database

  Variables                    Number of patients   *BIRC5* mRNA   *P*-value
  ---------------------------- -------------------- -------------- -----------
  **Age (years)**                                                  0.1561
  ≤51                          1392                 \-             
  \>51                         2210                 \-             
  **ER**                                                           \<0.0001
  Negative                     1559                 Increased      
  Positive                     3988                 \-             
  **PR**                                                           \<0.0001
  Negative                     946                  Increased      
  Positive                     1439                 \-             
  **HER-2**                                                        0.0152
  Negative                     1409                 \-             
  Positive                     201                  Increased      
  **Nodal status**                                                 0.2654
  Negative                     2493                 \-             
  Positive                     1562                 \-             
  **Basal-like status**                                            \<0.0001
  Non-basal-like               4200                 \-             
  Basal-like                   1144                 Increased      
  **Triple-negative status**                                       \<0.0001
  Non-triple-negative          4099                 \-             
  Triple-negative              374                  Increased      

Abbreviation: ER, estrogen receptor; PR, progesterone receptor.

*BIRC5* expression and prognosis in breast cancer patients {#sec3-3}
----------------------------------------------------------

We then investigated the prognostic value of *BIRC5* gene using the Kaplan--Meier Plotter. While breast cancer patients with lower level of *BIRC5* showed longer relapse-free survival and better overall survival, patients with increased *BIRC5* expression displayed shorter distant metastasis-free survival ([Figure 5](#F5){ref-type="fig"}A--C). By mining previously available data using the bc-GenExMiner, we analyzed the association between *BIRC5* and metastatic relapse-free survival. High level of *BIRC5* was significantly associated with elevated risk of metastatic relapse event (HR = 1.42, 95% CI: 1.33--1.52, *P*\<0.0001), as suggested by the forest plot ([Figure 5](#F5){ref-type="fig"}D).

![Survival curves derived from the Kaplan--Meier Plotter and forest plot generated from the bc-GenExMiner database evaluating the prognostic significance of *BIRC5*\
Analysis is shown for (**A**) relapse-free survival, (**B**) overall survival, (**C**) distant metastasis-free survival, and (**D**) metastatic relapse event.](bsr-40-bsr20193678-g5){#F5}

*BIRC5*--drug interaction network {#sec3-4}
---------------------------------

Given that high level of *BIRC5* conferred shorter survival in breast cancer patients, we then sought to investigate whether *BIRC5* and potential chemical drugs could modulate each other using the Comparative Toxicogenomics Database. *BIRC5*--drug interaction network indicated that a number of commonly used drugs could modulate the mRNA or protein expression of *BIRC5*. Specifically, chemotherapy agents including cisplatin, epirubicin, and doxorubicin, endocrine drugs such as tamoxifen and fulvestrant, and molecular targeting drugs lapatinib and palbociclib could decrease *BIRC5* level; whereas docetaxel was able to increase *BIRC5* expression ([Figure 6](#F6){ref-type="fig"}). By using the Comparative Toxicogenomics Database, several important *BIRC5*-related signaling pathways were also obtained including apoptosis, cell cycle, immune system, hippo signaling pathway, platinum drug resistance, pathways in cancer, and TP53 regulation ([Table 2](#T2){ref-type="table"}).

![*BIRC5*--drug interaction network obtained from the Comparative Toxicogenomics Database\
The network shows that several common drugs could modulate the mRNA or protein expression of *BIRC5*. For example, tamoxifen could decrease *BIRC5* expression (blue), while docetaxel could increase *BIRC5* level (red).](bsr-40-bsr20193678-g6){#F6}

###### Analysis of *BIRC5*-involved pathway terms

  Pathway ID             Pathway term
  ---------------------- --------------------------------------------------------------------------------------------------------------------------------------
  KEGG: hsa04210         Apoptosis
  REACT: R-HSA-1640170   Cell cycle
  REACT: R-HSA-69278     Cell cycle, mitotic
  REACT: R-HSA-1280215   Cytokine signaling in immune system
  REACT: R-HSA-74160     Gene expression
  REACT: R-HSA-212436    Generic transcription pathway
  KEGG: hsa04390         Hippo signaling pathway
  REACT: R-HSA-168256    Immune system
  REACT: R-HSA-6785807   Interleukin-4 and 13 signaling
  REACT: R-HSA-392499    Metabolism of proteins
  KEGG: hsa05200         Pathways in cancer
  KEGG: hsa01524         Platinum drug resistance
  REACT: R-HSA-597592    Post-translational protein modification
  REACT: R-HSA-449147    Signaling by interleukins
  REACT: R-HSA-194315    Signaling by Rho GTPases
  REACT: R-HSA-162582    Signaling transduction
  REACT: R-HSA-5633008   TP53 regulates transcription of cell death genes
  REACT: R-HSA-3700989   Transcriptional regulation by TP53
  REACT: R-HSA-6803205   TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain

Co-expression of *BIRC5* gene {#sec3-5}
-----------------------------

We finally investigated the co-expression of *BIRC5* gene using the Oncomine. *BIRC5* co-expression profile consists of a large cluster of 19574 genes from 336 breast cancer samples ([Figure 7](#F7){ref-type="fig"}A). The most highly correlated gene was *CDC20*. *CDC20* is an important regulatory cell cycle protein that activates the anaphase-promoting complex during mitosis, resulting in chromatid separation, and entrance of cell cycle into anaphase \[[@B24]\]. Data mining using the bc-GenExMiner revealed that *BIRC5* was positively correlated with *CDC20* ([Figure 7](#F7){ref-type="fig"}B). Such positive relationship was verified by analyzing TCGA database using the UCSC Xena ([Figure 7](#F7){ref-type="fig"}C,D).

![Co-expression of *BIRC5* gene\
(**A**) Co-expression profile of *BIRC5* analyzed using the Oncomine database. (**B**) Correlation between *BIRC5* and *CDC20* in breast cancer analyzed using the bc-GenExMiner software. (**C**) Heatmap of *BIRC5* and *CDC20* expression across PAM50 breast cancer subtypes using the TCGA data analyzed by the UCSC Xena browser. (**D**) Correlation between *BIRC5* and *CDC20* expression using the TCGA data analyzed by the UCSC Xena browser.](bsr-40-bsr20193678-g7){#F7}

Discussion {#sec4}
==========

Based on the high activation of *BIRC5* during tumorigenesis in various cancer types, treatment that targets *BIRC5* has been increasingly noticed as a promising therapeutic strategy \[[@B11]\]. However, the detailed expression pattern, potential function, prognostic value, and drug interaction network of *BIRC5* remain largely unclear in breast cancer.

First, our analysis using the Oncomine and TCGA databases revealed that *BIRC5* gene was higher expressed in breast cancer patients with respect to normal individuals. Moreover, Oncomine showed that *BIRC5* was significantly elevated in medullary breast carcinoma, invasive ductal breast carcinoma, invasive breast carcinoma, invasive ductal and invasive lobular breast carcinoma, breast carcinoma, invasive lobular breast carcinoma, and intraductal cribriform breast adenocarcinoma, compared with the corresponding normal tissues.

Second, we investigated the mechanisms of *BIRC5* dysregulation in breast cancer. After checking the DNA methylation status in TCGA, we found that *BIRC5* expression was negatively related to DNA methylation and higher promoter methylation level of *BIRC5* was expressed in breast cancer tissues. These observations indicated that DNA methylation might be an important mechanism of *BIRC5* dysregulation in breast cancer.

Then, we analyzed the relevance of *BIRC5* expression and different clinicopathological features. In the current work, estrogen receptor (ER) and progesterone receptor (PR) were negatively correlated with *BIRC5* expression. We also confirmed that high *BIRC5* level was associated with increased SBR and NPI, HER-2 positivity, basal-like status, and triple-negative status. Since patients with ER or PR negative, HER-2 positive, basal-like or triple-negative status generally display therapy insensitivity and inferior prognosis, our results suggested that lower expression of *BIRC5* may predict a satisfied clinical outcome of breast cancer.

Next, we checked the prognostic significance of *BIRC5* in breast cancer and demonstrated that high *BIRC5* expression was responsible for shorter relapse-free survival, worse overall survival, reduced distant metastasis-free survival, and increased risk of metastatic relapse event. This was based on survival curves obtained from the Kaplan--Meier Plotter and forest plot generated from the bc-GenExMiner database. Thus, our findings provided evidence that *BIRC5* could be a useful predictive prognostic marker for breast cancer. Indeed, several studies have reported *BIRC5* as a prognostic marker in breast cancer through experimental evidences \[[@B25]\]. However, the sample size is small and the evidence is insufficient for a single experimental paper. In the present work, we use several bioinformatics analysis tools, and the combination of bioinformatics analysis tools could provide more sufficient evidence for survival marker validation.

Provided the high *BIRC5* expression was involved in therapy response and worse prognosis, how to handle *BIRC5* overexpressed patients remains a lot of confusion. Here, we showed that a number of commonly used drugs were able to modulate *BIRC5.* For example, cisplatin, epirubicin, doxorubicin, tamoxifen, and lapatinib could decrease *BIRC5* level, while docetaxel could increase *BIRC5* expression. Hormone receptors were negatively correlated with *BIRC5* level as described in [Figure 4](#F4){ref-type="fig"}, and endocrine drug tamoxifen could reduce *BIRC5* level as shown in [Figure 6](#F6){ref-type="fig"}. Therefore, it is interesting to see whether hormone receptor positive patients with BIRC5 overexpression would benefit from *BIRC5* repression. We are currently enrolling patients (half cases with high *BIRC5* expression and half with low expression) to evaluate the effect of *BIRC5*. Remarkably, *BIRC5* has been found to confer resistance to chemotherapy and radiation. Targeting *BIRC5* including antisense oligonucleotide, ribozyme, RNA interference, and cancer vaccine in experimental models improved survival \[[@B11],[@B12]\]. Of *BIRC5*-related signaling pathways, 'hippo signaling pathway' and 'platinum drug resistance' have been previously confirmed to be responsible for drug resistance \[[@B28]\]. Further investigations are needed to more precisely elucidate the relevance of these signaling pathways.

As a key component of the spindle assembly checkpoint, *CDC20* has been reported in various malignant tumors and exhibits an important role in carcinogenesis and progression \[[@B24],[@B29]\]. High level of *CDC20* was found to be related to aggressive course of breast cancer and poor patient outcome, after 20 years follow-up of 445 patients \[[@B30]\]. After co-expression and correlation analysis using the Oncomine, bc-GenExMiner, and UCSC Xena web-based tools in the present study, we confirmed that *CDC20* gene was positively correlated with *BIRC5* expression. As a matter of fact, both *CDC20* and *BIRC5* were found to be co-expressed in lung adenocarcinoma, endometrial cancer, renal cell carcinoma, and thyroid carcinoma \[[@B31]\]. Given that cell cycle process is often coordinated with apoptotic proteins to maintain tissue homeostasis, silencing the expressions of cell cycle protein as well as anti-apoptotic proteins simultaneously could potentially lead to cell cycle arrest and reduce the proliferation of breast cancer cells. Recently, the *CDC20* and *BIRC5* small interfering RNAs delivered by additive polyplexes displayed novel therapy efficacy in breast cancer cell \[[@B35]\]. This pioneering research, along with our bioinformatics analysis, would add a piece of evidence to the emerging idea that *BIRC5* might contribute to breast cancer progression and drug resistance associated with *CDC20* expression.

Conclusion {#sec5}
==========

The present study validated that *BIRC5* was overexpressed in breast cancer patients and was responsible for a worse survival. *BIRC5* might be adopted as a promising predictive biomarker and potential therapeutic target with co-expressed *CDC20* gene. Further large-scale studies are needed to more precisely confirm the prognostic significance of *BIRC5* in breast cancer treatment.
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